2019–2020 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers

Image of Continuing Education Credits abbreviation. = Free Continuing Education

Date: Thursday, September 26, 2019

Time: 2:00pm-3:00pm (Eastern Time)

Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WC2922-092619—(Webcast) Clinician Outreach and Communication Activity (COCA) Calls/Webinars “2019–2020 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers” Thursday, September 26, 2019, please visit TCEO and follow these 9 Simple Steps by October 29, 2019.

To receive continuing education (CE) for WD2922-092619—(Web on demand) Clinician Outreach and Communication Activity (COCA) Calls/Webinars “2019–2020 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers” Thursday, September 26, 2019, please visit TCEO and follow these 9 Simple Steps by October 29, 2021.

Overview

Influenza remains a serious threat to children due to its potential to cause significant morbidity and mortality. More than 125 influenza-associated deaths in children were reported to the Centers for Disease Control and Prevention (CDC) during the 2018–2019 influenza season. Clinicians play a critical role in taking action to immunize children, the children’s family members and caregivers, and themselves. The early use of antivirals in children can reduce the duration of symptoms and prevent serious complications of influenza. However, immunization remains the most effective way to prevent influenza illness and its complications, including death.

During this COCA call, subject matter experts from the American Academy of Pediatrics (AAP) and CDC will discuss strategies pediatric providers can use to improve influenza prevention and control in children for the 2019–2020 influenza season.

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC’s role in the topic covered during the presentation.
  3. Describe the topic’s implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of health care providers.

 

Activity Specific Objectives

  1. Examine data from the 2018–2019 U.S. influenza season to inform preparations for the 2019–2020 influenza season.
  2. Highlight key recommendations in the AAP influenza policy statement, “Recommendations for Prevention and Control of Influenza in Children, 2019–2020” and in the CDC Advisory Committee on Immunization Practices’ document, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2019-2020 Influenza Season.”
  3. Discuss recommendations for using influenza antivirals in children.

Flor Munoz, MD, MSc, FAAP
Associate Professor of Pediatrics
Baylor College of Medicine, Houston, Texas
American Academy of Pediatrics

Fatimah Dawood, MD
Medical Officer
Epidemiology and Prevention Branch
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

A few minutes before the webinar begins on Thursday, September 26, 2019, please click the link below to join the webinar:
https://zoom.us/j/779319056external icon

Or iPhone one-tap:
US: +16468769923,,779319056#  or +16699006833,,779319056#

Or Telephone:
Dial(for higher quality, dial a number based on your current location):
US: +1 646 876 9923  or +1 669 900 6833

Webinar ID: 779 319 056

International numbers available: https://zoom.us/u/anixAVglVexternal icon

WC2922 0387-0000-19-159-L04-P  (must be completed by 10/29/2019)
WD2922 0387-0000-19-159-H04-P (must be completed by 09/26/2019)

  • Physicians
  • Nurses
  • Pharmacists
  • Veterinarians
  • Physician Assistants
  • Health Educators
  • Other Clinicians
  • Contact Information:coca@cdc.gov
  • Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
  • Method of Participation:You may participate in the educational activity by viewing the program information above.
  • Fees: Continuing Education (CE) is free.

Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity provides 1.0 contact hour.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

Image of acpe logo.CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-19-159-L04-P and enduring 0387-0000-19-159-H04-P   course category.

This activity has been designated as Knowledge-Based.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

For Certified Public Health Professionals (CPH)

The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of Dr. Munoz, and she wishes to disclose that she received royalty as author in “Up to Date”, Influenza chapter and she is a member of AAP COID, a member of Influenza working group at ACIP, a member of  DSMB for Moderna and Pfizer (vaccines, not influenza), and received research grants from NIH, CDC, and industry (Biocryst) to study respiratory viruses, epidemiology, prevention, and treatment strategies.

The Planning Committee discussed conflict of interest with Dr. Munoz to ensure there is no bias.

The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Munoz’s and Dr. Dawood’s discussion of antivirals for influenza as they are not licensed specifically for high risk, hospitalized patients; however, CDC and AAP recommend them for this population.

CDC did not accept commercial support for this continuing education activity.

Page last reviewed: April 1, 2019